ALKS

Elite Trades From Anywhere Elite Trades All Summer

$100 Off Your First Year Get Elite For Just $199.50

Today, 10:05 AMBofA downgrades Alkermes to Underperform from Neutral, sets $38 price target

Peers: NBIX ACAD INCY BIIB PFE VRTX BMY ABBV LLY MRK

| Held by: IJR IWM VTI VB AVUV FBT XBI VBK SPSM IJT

Index	RUT
Market Cap	8.87B
Enterprise Value	9.94B
Income	152.72M
Sales	1.56B
Book/sh	10.52
Cash/sh	3.07
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	2050
IPO	Jul 16, 1991

P/E	59.15
Forward P/E	92.91
PEG	-
P/S	5.68
P/B	5.06
P/C	17.32
P/FCF	39.98
EV/EBITDA	43.01
EV/Sales	6.36
Quick Ratio	1.70
Current Ratio	2.27
Debt/Eq	0.90
LT Debt/Eq	0.88
Option/Short	Yes / Yes

EPS (ttm)	0.90
EPS next Y	0.57
EPS next Q	-0.02
EPS this Y	-126.71%
EPS next Y	249.92%
EPS next 5Y	-1.84%
EPS past 3/5Y	- -
Sales past 3/5Y	9.90% 7.28%
EPS Y/Y TTM	-56.86%
Sales Y/Y TTM	3.21%
EPS Q/Q	-400.53%
Sales Q/Q	28.19%
Earnings	May 05 BMO
EPS/Sales Surpr.	26.74% 8.22%

Insider Own	2.22%
Insider Trans	-4.06%
Inst Own	107.52%
Inst Trans	-1.48%
ROA	4.82%
ROE	9.36%
ROIC	4.63%
Gross Margin	85.51%
Oper. Margin	12.28%
Profit Margin	9.78%
SMA20	16.17%
SMA50	33.34%
SMA200	61.98%
Trades

Shs Outstand	166.46M
Shs Float	162.98M
Short Float	11.02%
Short Ratio	7.25
Short Interest	17.96M
52W High	55.28 -3.75%
52W Low	25.17 111.41%
Volatility	5.72% 4.49%
ATR (14)	2.01
RSI (14)	77.59
Beta	0.28
Rel Volume	0.79
Avg Volume	2.48M
Volume	1,092,878

Perf Week	15.61%
Perf Month	33.21%
Perf Quarter	81.02%
Perf Half Y	86.54%
Perf YTD	90.14%
Perf Year	84.67%
Perf 3Y	82.67%
Perf 5Y	135.52%
Perf 10Y	31.60%
Recom	1.50
Target Price	49.44
Prev Close	55.08
Price	53.20
Change	-3.41%

Date	Action	Analyst	Rating Change	Price Target Change
Today	Downgrade	BofA Securities	Neutral → Underperform	$38
Feb-24-26	Initiated	Wolfe Research	Outperform	$45
Nov-11-25	Initiated	Truist	Buy	$50
Sep-26-25	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$44
Sep-03-25	Initiated	Wells Fargo	Overweight	$44
Jul-15-25	Initiated	Goldman	Buy	$43
Jun-17-25	Upgrade	UBS	Neutral → Buy	$42
May-28-25	Initiated	Needham	Buy	$45
Mar-13-25	Initiated	RBC Capital Mkts	Sector Perform	$40
Mar-04-25	Upgrade	UBS	Sell → Neutral	$21 → $38
Feb-11-25	Initiated	Deutsche Bank	Buy	$40
Nov-05-24	Upgrade	Stifel	Hold → Buy	$25 → $36
Jun-17-24	Initiated	TD Cowen	Buy	$34
Mar-19-24	Initiated	Robert W. Baird	Outperform	$37
Feb-20-24	Downgrade	UBS	Neutral → Sell	$25
Nov-20-23	Resumed	JP Morgan	Neutral	$33
Oct-24-23	Upgrade	Evercore ISI	In-line → Outperform
Oct-17-23	Initiated	UBS	Neutral	$31
Nov-03-22	Upgrade	Piper Sandler	Neutral → Overweight	$26 → $30
Oct-14-22	Upgrade	BofA Securities	Underperform → Neutral	$27 → $25

Show Previous Ratings

Today 12:01PM	BofA cuts ratings on four biopharma stocks over valuation and catalyst concerns (Investing.com)
09:44AM	Adobe downgraded, Roblox upgraded: Wall Street's top analyst calls (The Fly)
Jun-26-26 05:46AM	Alkermes incoming CEO has a plan to outplay Lilly and Takeda (BioPharma Dive)
Jun-17-26 04:15PM	Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026 (Business Wire)
Jun-15-26 07:00AM	Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe (Business Wire)
05:31AM	Loading…
Jun-12-26 05:31AM	Rapport fully prepared to launch seizure drug solo, CEO says (BioPharma Dive)
Jun-04-26 07:00AM	Alkermes to Present New Data on Alixorexton and LUMRYZ (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research (Business Wire)
Jun-03-26 04:05PM	Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference (Business Wire)
May-26-26 07:00AM	Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting (Business Wire)
May-21-26 07:00AM	Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences (Business Wire)
May-12-26 07:00AM	Alkermes Announces Positive Topline Results From REVITALYZ Phase 3 Study Evaluating LUMRYZ (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia (Business Wire) +7.95%
May-05-26 04:46PM	Alkermes plc Q1 2026 Earnings Call Summary (Moby) +6.09%
07:06AM	Alkermes: Q1 Earnings Snapshot (Associated Press)
07:00AM	Alkermes plc Reports First Quarter 2026 Financial Results (Business Wire)
Apr-21-26 04:05PM	Alkermes to Report First Quarter Financial Results on May 5, 2026 (Business Wire)
07:00AM	Loading…
Apr-16-26 07:00AM	Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting (Business Wire)
Apr-14-26 07:00AM	Findings From Long-Term Analysis of the Effects of LYBALVI (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry (Business Wire)
Apr-13-26 07:06AM	Preparation is key to understanding global trade compliance for trials (Clinical Trials Arena)
Apr-01-26 07:00AM	Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2 (Business Wire)
Mar-12-26 07:00AM	Alkermes Announces Inaugural Alkermes Pathways APN Research Awards Program (Business Wire)
Mar-11-26 05:11AM	New Strong Sell Stocks for March 11th (Zacks)
Mar-10-26 04:00PM	Alkermes to Present at the Stifel 2026 Virtual CNS Forum (Business Wire)
Mar-06-26 03:00AM	Biopharmas recent string of CEO splits (Pharma Voice)
Mar-02-26 10:02PM	Alkermes Pivots Deeper Into Sleep Medicine After Avadel Deal, Details Orexin Phase 3 at TD Cowen (MarketBeat)
Feb-26-26 11:40AM	Alkermes Down Despite Q4 Earnings Beat, Announces Leadership Change (Zacks)
Feb-25-26 02:03PM	Alkermes PLC (ALKS) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com) -7.04%
12:32PM	Alkermes plc Q4 2025 Earnings Call Summary (Moby)
12:30PM	Alkermes (ALKS) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
12:15PM	Alkermes (ALKS) Q4 Earnings and Revenues Top Estimates (Zacks)
11:02AM	Alkermes Q4 Earnings Call Highlights (MarketBeat)
07:43AM	Loading…
07:43AM	Alkermes: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026 (Business Wire)
06:55AM	Alkermes plc Announces CEO Succession Plan (Business Wire)
06:54AM	Alkermes Richard Pops to step down after three-decade run as CEO (BioPharma Dive)
Feb-24-26 04:00PM	Alkermes to Present at the TD Cowen 46th Annual Health Care Conference (Business Wire)
09:15AM	Wall Street's Insights Into Key Metrics Ahead of Alkermes (ALKS) Q4 Earnings (Zacks)
08:00AM	Here Are Tuesdays Top Wall Street Analyst Research Calls: Blackstone, Blue Owl Capital, Booking Holdings, Cheniere Energy, Comcast, Dominos Pizza, KeyCorp, Qualcomm, and More (24/7 Wall St.)
Feb-19-26 11:59AM	BHC Stock Down on Q4 Earnings Miss, Salix Drives Revenue Growth (Zacks)
07:34AM	ImmunityBio Wins EU Nod for Bladder Cancer Combo Therapy, Stock Up (Zacks)
Feb-18-26 11:31AM	FDA Accepts BMY's NDA for Iberdomide Combo in Multiple Myeloma (Zacks)
11:24AM	Krystal Biotech Q4 Earnings Beat Estimates, Revenues Miss Mark (Zacks)
09:41AM	EU Approves Novo Nordisk's Higher-Dose Wegovy for Obesity Patients (Zacks)
09:40AM	Is Alkermes (ALKS) Stock Outpacing Its Medical Peers This Year? (Zacks)
09:32AM	Cytokinetics Wins EU Approval for Cardiovascular Drug Myqorzo (Zacks)
Feb-17-26 12:10PM	Will Alkermes (ALKS) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Feb-13-26 01:11PM	Waters Q4 Earnings Surpass Estimates, Revenues Increase Y/Y (Zacks)
12:55PM	SNY Stock Falls After Board Suddenly Makes Leadership Change (Zacks)
11:53AM	VRTX's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales (Zacks)
10:33AM	Agios Pharmaceuticals Incurs Narrower-Than-Expected Q4 Loss (Zacks)
10:23AM	Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y (Zacks)
10:20AM	NVS Reports Positive Late-Stage Data on Kidney Disease Drug Vanrafia (Zacks)
10:19AM	ALNY Q4 Earnings Beat, Sales Miss Despite Y/Y Growth, Stock Down (Zacks)
10:04AM	CRSP Posts Wider-Than-Expected Loss in Q4, Sales Miss Estimates (Zacks)
Feb-12-26 10:38AM	MDGL Strengthens MASH Franchise With New Genetic Approaches (Zacks)
10:30AM	Zoetis Stock Gains After Q4 Earnings & Revenues Beat Estimates (Zacks)
07:30AM	Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market (Business Wire)
Feb-11-26 04:00PM	Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 25, 2026 (Business Wire)
12:57PM	Pharma companies left out of Trump's drug-pricing deals look for way in (Reuters)
10:45AM	MRNA Down Nearly 10% as FDA Refuses to Review Influenza Vaccine BLA (Zacks)
Feb-10-26 10:43AM	SNY's Rare Disease Drug Wins FDA Breakthrough and Japan Orphan Status (Zacks)
10:38AM	INCY Q4 Earnings Miss Estimates, Revenues Beat on Higher Product Sales (Zacks)
Feb-09-26 11:42AM	IMVT Posts Narrower-Than-Expected Q3 Loss, Pipeline in Focus (Zacks)
Feb-06-26 01:58PM	Mettler-Toledo Q4 Earnings Top Estimates, Sales Rise Y/Y (Zacks)
11:45AM	GSK Gets EU Approval for Expanded Use of Nucala in COPD (Zacks)
11:31AM	KOD Stock Up 24% in 3 Months: Here's What You Need to Know (Zacks)
Feb-05-26 11:42AM	Verastem Stock Rises Nearly 8% on Strong Q4 & 2025 Preliminary Results (Zacks)
10:49AM	Bristol-Myers Stock Up as Q4 Earnings and Revenues Beat Estimates (Zacks)
Feb-04-26 10:11AM	FDA Rejects AZN's Saphnelo SubQ Formulation, Priority Tag to Datroway (Zacks)
09:16AM	NVO Q4 Earnings & Sales Beat Estimates, Stock Down on Poor 2026 View (Zacks)
Feb-03-26 11:59AM	Sanofi's Venglustat Meets Primary Endpoints in Gaucher Disease Study (Zacks)
11:36AM	MRK Q4 Earnings & Sales Beat Estimates, Stock Down on Weak '26 View (Zacks)
10:43AM	NVO's CagriSema Outshines Semaglutide in Phase III Diabetes Study (Zacks)
09:27AM	Here's Why Gilead Sciences Stock Surged 21% in a Month (Zacks)
07:52AM	Acadia Expects Negative CHMP Opinion for Rett Syndrome Drug in EU (Zacks)
Feb-02-26 11:03AM	Ultragenyx Pharmaceutical Resubmits UX111 BLA for Sanfilippo Syndrome (Zacks)
09:40AM	Is Alkermes (ALKS) Outperforming Other Medical Stocks This Year? (Zacks)
Jan-30-26 10:24AM	FDA Accepts SMMT's Application Seeking Approval for NSCLC Drug (Zacks)
10:11AM	KYMR Initiates Dosing in Mid-Stage Asthma Study of Lead Candidate (Zacks)
Jan-29-26 11:52AM	HALO Rises Nearly 4% on Strong 2025 Preliminary Data and 2026 Guidance (Zacks)
11:23AM	TEVA's Q4 Earnings Beat, Branded Drugs Drive Revenue Growth (Zacks)
08:53AM	Biogen's Autoimmune Disease Candidate Gets FDA's Breakthrough Status (Zacks)
08:34AM	Are Options Traders Betting on a Big Move in Alkermes Stock? (Zacks)
Jan-28-26 09:45AM	NTLA Stock Up More Than 6% as FDA Lifts ATTRv-PN Study Clinical Hold (Zacks)
Jan-27-26 02:07PM	BHC's Late-Stage Liver Cirrhosis Studies Fail, Stock Down (Zacks)
12:15PM	Corvus Pharmaceuticals Stock Rallies 209% in a Month: Here's Why (Zacks)
10:53AM	RVMD Stock Tumbles as MRK Reportedly Withdraws Buyout Offer (Zacks)
10:50AM	SRPT Stock Up 8% on Positive Long-Term Data From Elevidys Study in DMD (Zacks)
Jan-23-26 11:13AM	CORT Rises as Relacorilant Meets OS Endpoint in Ovarian Cancer Study (Zacks)
Jan-22-26 02:17PM	Alkermes Stock Earns Technical Rating Upgrade (Investor's Business Daily)
11:39AM	MRNA & MRK's Personalized Cancer Therapy Delivers Strong 5-Year Data (Zacks)
03:09AM	Jim Cramer on Alkermes: "I Think It's a Hold, Maybe a Weak One" (Insider Monkey)
Jan-21-26 10:46AM	ImmunityBio Stock Soars on FDA Talks for Anktiva sBLA Resubmission (Zacks) +6.61%
10:31AM	FDA Grants Breakthrough Therapy Tag to LLY's Ovarian Cancer Candidate (Zacks)
10:12AM	NVO Expands Aspect Tie-Up to Advance Curative Diabetes Cell Therapies (Zacks)
Jan-19-26 10:36AM	ImmunityBio Shares Surge on Updated Durable Lymphoma Study Results (Zacks)
09:17AM	CytomX Stock Rises 31% in a Month: Here's What You Should Know (Zacks)
Jan-16-26 08:28PM	Lightning Round: Medline is 'unbelievable', it's a buy, says Jim Cramer (CNBC TV)
11:08AM	Mirum Stock Rises 7% in a Week: Here's What You Should Know (Zacks)
09:06AM	Erasca Stock Surges 42% in a Week: Here's What You Should Know (Zacks)
Jan-15-26 11:16AM	Apellis Stock Crashes 23% in a Week: Here's What You Should Know (Zacks)

Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.

Chairman & CEOMr. Richard F. Pops

Senior VP & CFOMr. Joshua Reed M.B.A.

Executive VPMr. Blair C. Jackson

Executive VPMr. David Joseph Gaffin J.D.

Executive VP of Research & Development and Chief Medical OfficerDr. Craig C. Hopkinson M.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Wright Christopher I	Director	Jun 12 '26	Sale	45.10	2,000	90,200	25,680	Jun 12 08:04 PM
Wright Christopher I	Officer	Jun 12 '26	Proposed Sale	45.10	2,000	90,200		Jun 12 04:19 PM
Gaffin David Joseph	EVP, CLO, Alkermes, Inc.	Jun 04 '26	Sale	43.05	2,034	87,564	229,524	Jun 04 05:00 PM
Gaffin David Joseph	Officer	Jun 04 '26	Proposed Sale	43.05	2,034	87,564		Jun 04 04:16 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Jun 01 '26	Option Exercise	19.34	5,000	96,700	86,389	Jun 01 07:26 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Jun 01 '26	Sale	41.67	9,000	375,044	77,389	Jun 01 07:26 PM
Hopkinson Craig C.	Officer	Jun 01 '26	Proposed Sale	41.67	9,000	375,043		Jun 01 04:29 PM
Parisi Samuel Joseph	VP, Finance (Interim PAO)	May 29 '26	Option Exercise	19.48	16,217	315,977	23,934	May 29 06:03 PM
Parisi Samuel Joseph	VP, Finance (Interim PAO)	May 29 '26	Sale	42.36	16,217	687,007	7,717	May 29 06:03 PM
Gaffin David Joseph	EVP, CLO, Alkermes, Inc.	May 04 '26	Sale	33.20	2,034	67,529	231,558	May 04 08:42 PM
Gaffin David Joseph	Officer	May 04 '26	Proposed Sale	33.20	2,034	67,529		May 04 04:30 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	May 01 '26	Option Exercise	19.34	5,000	96,700	90,389	May 01 09:05 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	May 01 '26	Sale	33.40	9,000	300,560	81,389	May 01 09:05 PM
Hopkinson Craig C.	Officer	May 01 '26	Proposed Sale	33.40	9,000	300,560		May 01 04:22 PM
Gaffin David Joseph	EVP, CLO, Alkermes, Inc.	Apr 06 '26	Sale	34.57	2,034	70,315	233,592	Apr 06 07:56 PM
Gaffin David Joseph	Officer	Apr 06 '26	Proposed Sale	34.57	2,034	70,315		Apr 06 04:16 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Apr 01 '26	Option Exercise	19.34	5,000	96,700	94,389	Apr 01 06:58 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Apr 01 '26	Sale	35.51	9,000	319,604	85,389	Apr 01 06:58 PM
Hopkinson Craig C.	Officer	Apr 01 '26	Proposed Sale	35.51	9,000	319,604		Apr 01 04:13 PM
Parisi Samuel Joseph	VP, Finance (Interim PAO)	Mar 02 '26	Sale	29.29	6,890	201,808	7,717	Mar 04 08:19 PM
Nichols Christian Todd	SVP, Chief Commercial Officer	Mar 02 '26	Sale	30.00	6,000	180,000	109,769	Mar 04 08:18 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Mar 02 '26	Option Exercise	19.34	5,000	96,700	98,389	Mar 04 08:16 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Mar 02 '26	Sale	29.72	9,000	267,485	89,389	Mar 04 08:16 PM
Gaffin David Joseph	EVP, CLO, Alkermes, Inc.	Mar 03 '26	Sale	29.76	2,034	60,532	235,626	Mar 04 08:15 PM
Gaffin David Joseph	EVP, CLO, Alkermes, Inc.	Mar 02 '26	Sale	29.29	2,034	59,576	237,660	Mar 04 08:15 PM
Gaffin David Joseph	Officer	Mar 03 '26	Proposed Sale	29.76	2,034	60,532		Mar 03 05:12 PM
Nichols Christian Todd	Officer	Mar 02 '26	Proposed Sale	30.00	6,000	180,000		Mar 02 05:15 PM
Gaffin David Joseph	Officer	Mar 02 '26	Proposed Sale	29.29	2,034	59,576		Mar 02 05:07 PM
Hopkinson Craig C.	Officer	Mar 02 '26	Proposed Sale	29.72	9,000	267,485		Mar 02 04:36 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Feb 02 '26	Option Exercise	19.34	5,000	96,700	66,740	Feb 02 08:52 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Feb 02 '26	Sale	33.93	9,000	305,384	57,740	Feb 02 08:52 PM
Cooke Shane	Director	Feb 02 '26	Option Exercise	31.64	61,200	1,936,368	164,944	Feb 02 08:48 PM
Cooke Shane	Director	Feb 02 '26	Sale	34.57	61,200	2,115,673	103,744	Feb 02 08:48 PM
Cooke Shane	Officer	Feb 02 '26	Proposed Sale	34.57	61,200	2,115,674		Feb 02 04:05 PM
Hopkinson Craig C.	Officer	Feb 02 '26	Proposed Sale	33.93	9,000	305,384		Feb 02 04:02 PM
Hopkinson Craig C.	Officer	Jan 08 '26	Proposed Sale	30.00	5,000	150,005		Jan 08 07:38 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Jan 08 '26	Option Exercise	19.34	5,000	96,700	66,740	Jan 08 05:23 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Jan 08 '26	Sale	30.00	5,000	150,005	61,740	Jan 08 05:23 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Jan 02 '26	Sale	28.00	4,000	112,000	61,740	Jan 02 04:39 PM
Hopkinson Craig C.	Officer	Jan 02 '26	Proposed Sale	28.00	4,000	112,000		Jan 02 04:36 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Dec 03 '25	Option Exercise	19.34	3,748	72,486	69,488	Dec 05 04:21 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Dec 03 '25	Sale	30.00	3,748	112,447	65,740	Dec 05 04:21 PM
Hopkinson Craig C.	Officer	Dec 03 '25	Proposed Sale	30.00	3,748	112,447		Dec 03 04:32 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Dec 01 '25	Sale	29.30	4,000	117,200	65,740	Dec 01 05:41 PM
Hopkinson Craig C.	Officer	Dec 01 '25	Proposed Sale	29.30	4,000	117,200		Dec 01 04:45 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Nov 03 '25	Option Exercise	19.34	5,000	96,700	78,740	Nov 03 04:37 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Nov 03 '25	Sale	30.38	9,000	273,442	69,740	Nov 03 04:37 PM
Hopkinson Craig C.	Officer	Nov 03 '25	Proposed Sale	30.38	9,000	273,442		Nov 03 04:35 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Oct 15 '25	Option Exercise	19.34	5,000	96,700	82,740	Oct 15 06:47 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Oct 15 '25	Sale	31.53	9,000	283,776	73,740	Oct 15 06:47 PM
Hopkinson Craig C.	Officer	Oct 15 '25	Proposed Sale	31.53	9,000	283,777		Oct 15 04:07 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

$100 Off Your First Year Get Elite For Just $199.50

Alkermes plc

Upgrade your Finviz experience